| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 10 | +70.00% | -5.43% | +1.59% | -7.03% | -6.53% | — |
| 14d | 10 | +100.00% | -12.77% | +2.37% | -15.15% | -16.32% | — |
| 30d | 10 | +80.00% | -6.07% | +4.38% | -10.45% | -9.44% | — |
| 60d | 10 | +80.00% | -16.10% | +2.25% | -18.35% | -23.30% | — |
| 90d | 10(2 pending) | +87.50% | -20.06% | +4.91% | -24.97% | -32.95% | — |
| 180d | 10(2 pending) | +87.50% | -9.07% | +10.85% | -19.93% | -23.95% | — |
| 1y | 10(3 pending) | +100.00% | -23.42% | +21.46% | -44.88% | -45.72% | — |
| 2y | 10(3 pending) | +100.00% | -68.58% | +38.63% | -107.20% | -106.83% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 47,775 | $20.03 | $956.9K | 2,877,118 | Jul 1, 2026 | Jul 2, 2026 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 51,873 | $18.23 | $945.6K | 2,924,893 | Apr 13, 2026 | Apr 14, 2026 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 98,127 | $18.41 | $1.81M | 2,976,766 | Apr 10, 2026 | Apr 14, 2026 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | PURCHASEGRANT Stock grant | 520,342 | — | — | 520,342 | Jan 7, 2026 | Jan 9, 2026 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 5,836 | — | — | 0 | Dec 19, 2025 | Dec 22, 2025 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 196,316 | — | — | 0 | Dec 19, 2025 | Dec 22, 2025 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | PURCHASE Chief Executive Officer | 196,316 | — | — | 3,074,893 | Dec 19, 2025 | Dec 22, 2025 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 70,000 | $14.49 | $1.01M | 2,878,577 | Dec 9, 2025 | Dec 10, 2025 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 130,000 | $15.08 | $1.96M | 2,948,577 | Dec 8, 2025 | Dec 10, 2025 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | PURCHASEGRANT Stock grant | 95,763 | — | — | 3,078,577 | Feb 27, 2025 | Mar 3, 2025 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 4,740 | $55.89 | $264.9K | 2,982,814 | Feb 29, 2024 | Feb 29, 2024 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 56,065 | $55.00 | $3.08M | 2,987,554 | Feb 28, 2024 | Feb 29, 2024 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 62,810 | $55.00 | $3.45M | 3,043,619 | Feb 27, 2024 | Feb 29, 2024 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 1,125 | $55.27 | $62.2K | 3,106,429 | Feb 21, 2024 | Feb 23, 2024 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 20,000 | $57.44 | $1.15M | 3,107,554 | Feb 20, 2024 | Feb 20, 2024 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 20,000 | $60.15 | $1.20M | 3,127,554 | Feb 16, 2024 | Feb 20, 2024 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE10b5-1 10b5-1 plan | 20,000 | $60.18 | $1.20M | 3,147,554 | Feb 15, 2024 | Feb 20, 2024 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 140,071 | — | — | 217,374 | Oct 1, 2023 | Oct 3, 2023 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 90,000 | — | — | 0 | Oct 1, 2023 | Oct 3, 2023 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | PURCHASE Chief Executive Officer | 3,027,483 | — | — | 3,027,483 | Oct 1, 2023 | Oct 3, 2023 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 3,027,483 | — | — | 0 | Oct 1, 2023 | Oct 3, 2023 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | SALE Chief Executive Officer | 4,164 | — | — | 5,836 | Oct 1, 2023 | Oct 3, 2023 ↗ | View → |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | PURCHASE Chief Executive Officer | 140,071 | — | — | 3,167,554 | Oct 1, 2023 | Oct 3, 2023 ↗ | View → |